InvestorsHub Logo
Followers 88
Posts 1175
Boards Moderated 0
Alias Born 09/10/2017

Re: None

Wednesday, 08/07/2019 1:05:56 PM

Wednesday, August 07, 2019 1:05:56 PM

Post# of 4817
Okay, let the upgrades begin . . . Err scratch that. Let the reiterations begin!

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Antares Pharma (ATRS), with a price target of $4.50. (same PT he's had since last October)